Evaluating H295R steroidogenesis assay data for robust interpretation

Regul Toxicol Pharmacol. 2023 Sep:143:105461. doi: 10.1016/j.yrtph.2023.105461. Epub 2023 Jul 23.

Abstract

The in vitro H295R steroidogenesis assay (OECD TG 456) is used to determine a chemical's potential to interfere with steroid hormone synthesis/metabolism. As positive outcomes in this assay can trigger significant higher tiered testing, we compiled a stakeholder database of reference and test item H295R data to characterize assay outcomes. Information concerning whether a Level 5 reproductive toxicity study was triggered due to a positive outcome in the H295R assay was also included. Quality control acceptance criteria were not always achieved, suggesting this assay is challenging to conduct within the guideline specifications. Analysis of test item data demonstrated that pairwise significance testing to controls allowed for overly sensitive statistically significant positive outcomes, which likely contribute to the assay's high positive hit rate. Complementary interpretation criteria (e.g., 1.5-fold change threshold) markedly reduced the rate of equivocal and positive outcomes thus improving identification of robust positive effects in the assay. Finally, a case study (positive H295R outcome and no endocrine adversity in vivo) is presented, which suggests that stricter data interpretation criteria could refine necessary in vivo follow-up testing. Overall, the described additional criteria could improve H295R data interpretation and help inform on how to best leverage this assay for regulatory purposes.

Keywords: Assay performance; Endocrine disruption; In vitro; OECD TG456; Steroidogenesis.

MeSH terms

  • Cell Line, Tumor
  • Endocrine Disruptors* / toxicity
  • Endocrine System*

Substances

  • Endocrine Disruptors